Cyclin-Dependent Kinase 4/6 (Cdk4/6) Inhibitors: Perspectives in Cancer Therapy and Imaging

Author(s): F. Graf, B. Mosch, L. Koehler, R. Bergmann, F. Wuest, J. Pietzsch

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 10 , Issue 6 , 2010

Become EABM
Become Reviewer
Call for Editor


Cyclin-dependent kinases 4 and 6 (Cdk4/6) are important components of cell cycle activation and control in early G1 phase. Both enzymes and their regulators, e.g., cyclins, play critical roles in embryogenesis, homeostasis, and cancerogenesis. Cdk4/6 are attractive targets for cancer treatment. Recently, numerous selective small molecule inhibitors of Cdk4/6 have been developed. The potential of Cdk4/6 inhibitors, particularly, pyrido[2,3-d]pyrimidine derivatives, as both anti-cancer drugs and 124I- and 18F-radiolabeled tracers for cancer imaging using positron emission tomography is discussed.

Keywords: Cell cycle regulation, pyrido[2,3-d]pyrimidine, iodine-124, fluorine-18, radiolabeling, positron emission tomography

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2010
Published on: 01 March, 2012
Page: [527 - 539]
Pages: 13
DOI: 10.2174/138955710791384072
Price: $65

Article Metrics

PDF: 37